Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113071 · ClinicalTrials.gov registry record · Phase 1
Safety and Activity of Digoxin With Decitabine in Adult AML and MDS
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03113071 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT03113071, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in distinct epigenetic alterations in AML/MDS patients.
Interventions
- DRUG Decitabine
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2019-03-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03113071
The ClinicalTrials.gov registry entry for NCT03113071 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT03113071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03113071 about?
NCT03113071 is a clinical study titled "Safety and Activity of Digoxin With Decitabine in Adult AML and MDS". The primary hypothesis is that digoxin can be safely added to decitabine and will increase the response rates in medically unfit patients with newly diagnosed AML/MDS or those with relapsed/refractory AML/MDS. Furthermore, it is hypothesized that the addition of digoxin to decitabine will result in ...
What is the current status of trial NCT03113071?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-06-02. Estimated completion is 2019-03-11.
What interventions are being tested in trial NCT03113071?
The interventions under investigation include: Decitabine (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT03113071?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.